U.S. Firm Acquires Novozymes Biopharma Sweden

Biopharmaceutical company Repligen (Waltham, MA) says it has signed a definitive agreement to acquire Novozymes Biopharma Sweden (Lund, Sweden), a business of Novozymes (Bagsvaerd, Denmark), for €17 million ($24 million) and future potential milestone payments of €4 million. The acquisition will help Repligen to become a leading supplier of products for manufacturing biologic drugs. The transaction is expected to be finalized during the fourth quarter of 2011. The combined company is expected to generate total sales of about $50 million in fiscal year...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers